Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $7.4, accompanied by a high estimate of $11.00 and a low estimate of $5.00.

Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 GlobeNewswire Apr 22, 2025, 5:34:17 PM ...

Discover real-time Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead ...